文献速递间质性肺疾病

精准医学在间质性肺疾病中的作用

The role of precision medicine in interstitial lung disease.
PubMed 文献 · Eur Respir J · 2022-09-07

本文综述了精准医学在间质性肺疾病(ILD)管理中的潜在应用。文章指出,基于生物标志物的精准医学方法在ILD诊断、分期、预后和治疗反应评估方面具有前景,人工智能可能进一步优化个体化治疗算法,但与肿瘤学等领域相比,ILD精准医学仍处于起步阶段。

要点

  • ILD管理需转向个体化策略,涵盖诊断分类与疾病行为。
  • 基于生物标志物的精准医学方法在ILD中前景广阔。
  • 人工智能可能提升基于诊断和疾病过程的预后评估能力。

核心结论

  • 精准医学在ILD中的应用仍处于起步阶段,但生物标志物和人工智能有望推动个体化治疗策略的发展。

主要发现

  • 过去20年对ILD异质性的深入理解凸显了个体化治疗策略的必要性。
  • 支持ILD诊断的稳健、大规模生物标志物技术已开发,分期、预后和治疗反应评估的应用正在涌现。
  • 人工智能可能将个体化治疗算法提升到前所未有的水平。

临床怎么用

  • 临床可关注基于生物标志物的诊断和预后评估工具,并考虑人工智能辅助的个体化治疗决策。

局限性

  • 与肿瘤学等治疗领域相比,ILD精准医学仍处于起步阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of interstitial lung disease (ILD) may benefit from a conceptual shift. Increased understanding of this complex and heterogeneous group of disorders over the past 20 years has highlighted the need for individualised treatment strategies that encompass diagnostic classification and disease behaviour. Biomarker-based approaches to precision medicine hold the greatest promise. Robust, large-scale biomarker-based technologies supporting ILD diagnosis have been developed, and future applications relating to staging, prognosis and assessment of treatment response are emerging. Artificial intelligence may redefine our ability to base prognostic evaluation on both diagnosis and underlying disease processes, sharpening individualised treatment algorithms to a level not previously achieved. Compared with therapeutic areas such as oncology, precision medicine in ILD is still in its infancy. However, the heterogeneous nature of ILD suggests that many relevant molecular, environmental and behavioural targets may serve as useful biomarkers if we are willing to invest in their identification and validation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Maher TM, Nambiar AM, Wells AU, et al. The role of precision medicine in interstitial lung disease. Eur Respir J. 2022. PMID: 35115344. doi:10.1183/13993003.02146-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。